Prestige Consumer Healthcare Inc. Update: Earnings and New Growth Plans

If you follow Prestige Consumer Healthcare—the company behind brands like Monistat, Dramamine, and Clear Eyes—there is big news to digest. The company just shared its full-year financial results and announced a new acquisition. Here is the breakdown of what you need to know.

1. The Big Moves

Prestige has two major updates that define their current direction:

• The Acquisition: They signed a deal to buy LaCorium Health, an Australian leader in therapeutic skin care, for $150 million in cash.
• The Earnings: On May 13, 2026, the company released results for the fiscal year ending March 31, 2026. Total revenue was $1.05 billion, a 4.3% drop from the previous year, with a total profit of $218.6 million.

2. Why It Matters for Your Portfolio

These moves show that Prestige is actively trying to grow beyond its current medicine cabinet staples.

• Strategic Expansion: Prestige is buying LaCorium to enter the therapeutic skin care market. Because LaCorium is already profitable, Prestige expects this deal to be "accretive"—meaning it should increase their total profit within the first year of ownership.
• The "Supply Chain" Factor: The revenue dip wasn't due to a lack of demand, but rather production bottlenecks at the Pillar5 eye care plant, which hurt Clear Eyes sales. The company is currently upgrading this facility to resolve these issues.
• Capital Allocation: Despite the dip in sales, the company spent $156 million buying back its own shares. This is a classic signal that management believes the stock is undervalued and is confident in their long-term cash flow.

3. What to Watch in 2027

The company is in a transition phase, moving past last year’s operational "noise" to focus on future growth. Here is what to look for:

• Growth Targets: Management is forecasting a "return to growth" in 2027, aiming for sales increases of 1% to 3% and a profit of $4.42 to $4.51 per share.
• Portfolio Expansion: Beyond LaCorium, they are also working to finalize the acquisition of Breathe Right to bolster their respiratory health portfolio.
• Operational Execution: The real test for investors will be whether they can successfully integrate these new brands while simultaneously restoring full production capacity at their eye care facilities.

4. The Bottom Line

Prestige is using its strong financial foundation to buy new brands while managing debt and returning cash to shareholders.

Investment Perspective: If you are looking at this company, the primary question isn't just about the past year's revenue dip—it’s about execution. Watch for news on the LaCorium deal closing (expected in the second quarter of 2027) and updates on the Pillar5 factory upgrades. If they hit their 2027 profit targets, it would suggest that the current "transition" is working.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before making any trades.